DrugCards, Tallinn (2025)

23/09/2025

𝗗𝗿𝘂𝗴 𝘀𝗮𝗳𝗲𝘁𝘆 𝗱𝗮𝘁𝗮𝗯𝗮𝘀𝗲𝘀… 🗄️
They may sound technical, but in reality, they’re the backbone of patient safety.
📬 Every adverse reaction, every XML file, every compliance check runs through them. Without these systems, pharmacovigilance wouldn’t work.

🤔The challenge? Most drug safety databases are restrictive, expensive, and inflexible.
🔥Now imagine one with unlimited users, unlimited cases, and fair pricing.

That’s not just innovation - it’s the future of patient safety.
👉 Read more on the DrugCard blog: https://drug-card.io/blog/drug-safety-database-without-limits/

16/09/2025

🔍 𝗛𝗼𝘄 𝗱𝗼 𝘄𝗲 𝘀𝗼𝗹𝘃𝗲 𝘁𝗵𝗲 𝗽𝘂𝘇𝘇𝗹𝗲 𝗼𝗳 𝗶𝗻𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝘀𝗮𝗳𝗲𝘁𝘆 𝗿𝗲𝗽𝗼𝗿𝘁𝘀?
In pharmacovigilance, every missing detail can change the whole picture. Standard questionnaires help, but sometimes they are not enough. That’s where 𝙎𝙥𝙚𝙘𝙞𝙛𝙞𝙘 𝘼𝙙𝙫𝙚𝙧𝙨𝙚 𝙍𝙚𝙖𝙘𝙩𝙞𝙤𝙣 𝙁𝙤𝙡𝙡𝙤𝙬-𝙪𝙥 𝙌𝙪𝙚𝙨𝙩𝙞𝙤𝙣𝙣𝙖𝙞𝙧𝙚𝙨 (Specific AR FUQs) come in - tailored tools📄 designed to capture the exact information needed to assess risks and protect patients.

🔥A new blog post on the DrugCard blog explores how these questionnaires work, why they matter, and how they transform vague case reports into actionable safety insights.

👉 Read more here: https://drug-card.io/blog/specific-adverse-reaction-follow-up-questionnaires-in-pharmacovigilance/

09/09/2025

𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝘃𝗶𝗴𝗶𝗹𝗮𝗻𝗰𝗲 𝗵𝗮𝘀 𝗶𝘁𝘀 𝗼𝘄𝗻 𝗹𝗮𝗻𝗴𝘂𝗮𝗴𝗲 - 𝗱𝗼 𝘆𝗼𝘂 𝘀𝗽𝗲𝗮𝗸 𝗶𝘁?
👨🏻‍💻When starting a career in PV, the first challenge is not databases, regulations, or reports. It’s the terminology.

🤔What’s the difference between an AE and an ADR? Why is an SAE not the same as “serious-sounding”? How do MedDRA, ICSRs, RMPs, and signals fit into daily safety work?

🔥Our new DrugCard blog post, “Pharmacovigilance Terminology Key Definitions for Beginners,” breaks it all down clearly and simply.

🔗 Read here 👉 https://drug-card.io/blog/pharmacovigilance-terminology-key-definitions-for-beginners/

08/09/2025

Amsterdam, we’re coming 🚀 And we’re 𝗯𝘂𝘇𝘇𝗶𝗻𝗴. 🇳🇱

In just a few weeks, DrugCards will join thousands of peers at Europe’s biggest Drug Safety conference - World Drug Safety Congress Europe, October 7–8, 2025.

Why we’re excited:
- Nothing beats real conversations with PV leaders who care as much as we do.
- We get to swap stories, compare notes, and turn tough safety workflows into simple, auditable processes.
- And yes…we’re nerds about literature monitoring - and proud of it 😁 .

Stop by 𝗕𝗼𝗼𝘁𝗵 𝟳𝟵 for a hands-on look at how DrugCard automates global & local literature screening so MAHs and CROs stay audit-ready without drowning in manual work.

🎯 Also attending? We’d love to meet you. 𝗗𝗠 𝘂𝘀 𝘁𝗼 𝗯𝗼𝗼𝗸 𝗮 𝟭:𝟭 - we’ll tailor a quick walkthrough to your use case (sources, coverage, audit trails, exports, dashboards - your call).

See you at the RAI. Can’t wait to connect!

hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag

02/09/2025

𝗛𝗮𝘃𝗲 𝘆𝗼𝘂 𝗵𝗲𝗮𝗿𝗱 𝗼𝗳 “𝗢𝘇𝗲𝗺𝗽𝗶𝗰 𝗳𝗮𝗰𝗲”?
🗣️It’s one of the most talked-about buzzwords of the year - popping up in celebrity interviews, lifestyle magazines, and medical discussions. But what does it really mean beyond the headlines?

🧠Our latest DrugCard blog post examines this phenomenon, where medicine, beauty, and culture unexpectedly intersect. Thanks to 📚literature monitoring, we can see how scientific publications explore such trends with fresh insights.

💡 Read the full article here 👉 https://drug-card.io/blog/ozempic-face-it-s-more-than-just-a-cosmetic-concern/

26/08/2025

𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗟𝗲𝗻𝘀 𝗦𝗮𝗳𝗲𝘁𝘆 𝗠𝗼𝗿𝗲 𝗧𝗵𝗮𝗻 𝗠𝗲𝗲𝘁𝘀 𝘁𝗵𝗲 𝗘𝘆𝗲
Over 140 million people worldwide rely on contact lenses every day. Caring for them may feel routine, yet even minor lapses in hygiene can turn convenience into risk.

🚑From discomfort to sight-threatening infections, contact lens safety remains a critical patient safety concern.
🧠Our recent blog post explores hidden risks, real-world cases, and what pharmacovigilance specialists can learn from them.

📖Read the full article: https://drug-card.io/blog/contact-lens-safety-from-a-pharmacovigilance-perspective/

19/08/2025

🕶️𝗠𝗮𝘀𝗸𝗶𝗻𝗴 𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹 𝗱𝗮𝘁𝗮 𝗶𝗻 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝘃𝗶𝗴𝗶𝗹𝗮𝗻𝗰𝗲: 𝗽𝗿𝗶𝘃𝗮𝗰𝘆 𝘃𝘀. 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝘀𝗮𝗳𝗲𝘁𝘆
Not all details in ICSRs should be visible - and not all should be hidden.
Since July 2025, the 🇪🇺EMA has enforced new rules on handling personal data in ICSRs. Some fields must be masked, some left blank, and others remain visible - because patient safety depends on it.

💡The new EMA guidance on masking of personal data in pharmacovigilance changes the way we balance data protection with drug safety.
📖 Read our latest DrugCard blog to learn what MAHs and PV specialists must know: https://drug-card.io/blog/masking-of-personal-data-in-pharmacovigilance/

12/08/2025

𝗪𝗵𝘆 𝗗𝗿𝘂𝗴 𝗜𝗻𝗳𝘂𝘀𝗶𝗼𝗻 𝗦𝗽𝗲𝗲𝗱 𝗠𝗶𝗴𝗵𝘁 𝗕𝗲 𝗬𝗼𝘂𝗿 𝗕𝗹𝗶𝗻𝗱 𝗦𝗽𝗼𝘁 𝗶𝗻 𝗔𝗗𝗥𝘀
In pharmacovigilance, we track what drugs patients take, when, and how much. But how often do we consider how fast the drug 💉is infused?

🚨Infusion rate can be the difference between a routine therapy and a sudden, life-threatening reaction. Yet, most ADR reports don’t capture this crucial detail - meaning critical clues to causality may slip through the cracks.

💡Read more in our new blog post – https://drug-card.io/blog/drug-infusion-rate-and-how-speed-affects-adrs/

05/08/2025

𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻 𝗜𝘀𝗻’𝘁 𝗔𝗹𝘄𝗮𝘆𝘀 𝗦𝗮𝗳𝗲
Most of us think about drug safety in terms of side effects while taking 💊medications. But what happens when a patient stops a drug - sometimes abruptly, without medical advice?

Drug discontinuation 🚫abruptly can cause serious risks like withdrawal and rebound effects, which are often overlooked in drug safety. For pharmacovigilance specialists, monitoring doesn’t end at the last dose.

🔥Check out our latest blog post on the DrugCard platform to learn more 👉 https://drug-card.io/blog/drug-discontinuation-needs-more-attention-in-drug-safety-monitoring/

29/07/2025

𝗣𝗿𝗲𝗰𝗮𝘂𝘁𝗶𝗼𝗻𝗮𝗿𝘆 𝗺𝗲𝗮𝘀𝘂𝗿𝗲𝘀 𝗶𝗻 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝘃𝗶𝗴𝗶𝗹𝗮𝗻𝗰𝗲 𝗮𝗿𝗲𝗻’𝘁 𝗷𝘂𝘀𝘁 𝗽𝗿𝗼𝘁𝗼𝗰𝗼𝗹𝘀 - 𝘁𝗵𝗲𝘆 𝘀𝗮𝘃𝗲 𝗹𝗶𝘃𝗲𝘀.
In pharmacovigilance, waiting for perfect data can cost lives. That’s why precautionary measures - early, decisive steps taken by regulatory authorities - are essential to managing emerging 💊drug safety risks.

🔥Our latest blog post on the DrugCard platform explores a compelling real-world example where global agencies swiftly responded to serious adverse events linked to a vaccine, protecting vulnerable 👵🏻populations while investigations were ongoing.
🔗 https://drug-card.io/blog/precautionary-measures-in-pv-show-how-safety-comes-first/
💪Stay informed and learn why early, decisive action is key to drug safety.

22/07/2025

𝗡𝗼𝗰𝗲𝗯𝗼 𝗘𝗳𝗳𝗲𝗰𝘁 𝗠𝗶𝘀𝗹𝗲𝗮𝗱𝘀 𝗔𝗗𝗥 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻
Not all adverse💊 drug reactions come from the drug itself.

📄The latest article on the DrugCard platform blog dives into the nocebo effect - how patient 🧠expectations can mimic real adverse drug reactions, complicate pharmacovigilance, and lead to therapy failure: https://drug-card.io/blog/nocebo-effect-or-when-the-mind-becomes-the-side-effect/

💡This psychological phenomenon is more common than you think - and it’s quietly impacting drug safety data.

15/07/2025

𝗔𝗱𝗱𝗲𝗻𝗱𝘂𝗺 𝘁𝗼 𝘁𝗵𝗲 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗢𝘃𝗲𝗿𝘃𝗶𝗲𝘄 𝗮𝘀 𝗮 𝗚𝗿𝗼𝘄𝘁𝗵 𝗗𝗶𝗮𝗿𝘆 𝗳𝗼𝗿 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀💊
Preparing an ACO isn't just regulatory - it's storytelling.
It's where we tell the story of a drug: how it grew, what challenges it faced, and how safe and effective it remained over time. It's almost like describing a 👶child's development - only with clinical trials, PSURs, and global safety data.

📁Our latest blog post explores why the ACO is essential for MA renewals and variations: https://drug-card.io/blog/addendum-to-the-clinical-overview-supporting-safety-decisions/

📍And don't forget: innovative and intelligent tools make the process easier. With 𝙎𝙞𝙢𝙥𝙡𝙚 𝙎𝙚𝙖𝙧𝙘𝙝 𝙗𝙮 𝘿𝙧𝙪𝙜𝘾𝙖𝙧𝙙🔥, specialists can quickly find relevant literature to support safety assessments.

DrugCards

23/09/2025

16/09/2025

09/09/2025

08/09/2025

02/09/2025

26/08/2025

19/08/2025

12/08/2025

05/08/2025

29/07/2025

22/07/2025

15/07/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category